EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

NETest in advanced high‐grade gastroenteropancreatic neuroendocrine neoplasms

H Sorbye iD, G O Hjortland, L W Vestermark, A Sundlov, J Assmus, A Couvelard, A Perren, S W Langer

Journal of Neuroendocrinology · 2024

DOI: 10.1111/jne.13428 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Neuroendocrinology, 2024. Verfasst von H Sorbye und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Haukeland University Hospital and Department of Clinical Science, University of Bergen, Bergen, Norway. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Neuroendocrine Tumors, Intestinal Neoplasms, Stomach Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Molecular blood biomarkers are lacking for high‐grade (HG) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN). To histologically distinguish between neuroendocrine carcinoma (NEC), neuroendocrine tumors G3 (NET G3), adenocarcinoma and MINEN is often challenging. The mRNA‐based NETest has diagnostic, prognostic and predictive value in neuroendocrine tumors G1‐2 but has not been studied in HG GEP‐NEN. Patients with advanced HG GEP‐NEN were prospectively included in an observational study. A blood sample was collected before the start of chemotherapy and pseudonymised before NETest was performed. NETest results are expressed as an activity index (NETest score) from 0 to 100. The normal score cut‐off is 20. Histological sections were pseudonymised before centralized pathological re‐evaluation. Samples from 60 patients were evaluable with the NETest. Main primary tumor sites were colon (14), rectum (12), pancreas (11) and esophagus (7). Re‐classification: 30 NEC, 12 NET G3, 3 HG‐NEN ambiguous morphology, 8 MiNEN, 3 adenocarcinomas with neuroendocrine differentiation (ADNE), 3 adenocarcinomas and 1 NET G2. Elevated NETest (>20) was seen in 38/45 (84%) HG GEP‐NEN, all 17 large‐cell NEC (100%), 11/13 (85%) small‐cell NEC, all ambiguous cases and 7/12 (64%) NET G3. NETest was elevated in 5/8 (63%) MiNEN, 2/3 ADNE, however not in 3 adenocarcinomas. Median survival was 10.2 months (9.6–10.8 95%CI) for evaluable HG GEP‐NEN treated with palliative chemotherapy ( n = 39), and survival was significantly shorter in patients with NETest >60 with an OS of only 6.5 months. This is the first study to evaluate use of the NETest in advanced HG GEP‐NEN. The NETest was almost always elevated in GEP‐NEC and in all large‐cell NEC. The NETest was also frequently elevated in NET G3 and MiNEN, however cases were limited. Baseline NETest was not predictive for benefit of chemotherapy, however a NETest >60 was prognostic with a shorter survival for patients receiving chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsNeuroendocrine TumorsIntestinal NeoplasmsStomach NeoplasmsHumansMaleFemaleMiddle AgedAgedAdultAged, 80 and overNeoplasm GradingProspective StudiesBiomarkers, Tumor

Stichwörter der Autor:innen

NECNET G3NETestgastroenteropancreatichigh‐grade neuroendocrine neoplasms

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Oncology, Haukeland University Hospital and Department of Clinical Science, University of Bergen, Bergen, Norway.
  • Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Danish Medicines Agency, Copenhagen, Denmark.
  • Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
  • Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway.
  • Department of Pathology, AP-HP Bichat Hospital, Université Paris Cité, Paris, France.

ORCID-Profile: H Sorbye

Zitieren

APA

Sorbye, H., Hjortland, G. O., Vestermark, L. W., Sundlov, A., Assmus, J., Couvelard, A., Perren, A., & Langer, S. W. (2024). NETest in advanced high‐grade gastroenteropancreatic neuroendocrine neoplasms. Journal of Neuroendocrinology. https://doi.org/10.1111/jne.13428

Vancouver

Sorbye H, Hjortland GO, Vestermark LW, Sundlov A, Assmus J, Couvelard A, et al. NETest in advanced high‐grade gastroenteropancreatic neuroendocrine neoplasms. Journal of Neuroendocrinology. 2024. doi:10.1111/jne.13428

BibTeX
@article{Sorbye2024,
  author = {Sorbye, H and Hjortland, G O and Vestermark, L W and Sundlov, A and Assmus, J and Couvelard, A and Perren, A and Langer, S W},
  title = {NETest in advanced high‐grade gastroenteropancreatic neuroendocrine neoplasms},
  journal = {Journal of Neuroendocrinology},
  year = {2024},
  doi = {10.1111/jne.13428}
}
Kostenlos starten →